Spectral Diagnostics (EDTXF) Stock Price, News & Analysis

Company Overview

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $0.59 to $0.59
• 50-Day Range: $0.56 to $0.65
• 52-Week Range: $0.32 to $0.65
• Volume: 380 shs
• Average Volume: 15,054 shs
• Market Capitalization: $168.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Spectral Diagnostics Stock Analysis - MarketRank™

Spectral Diagnostics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Spectral Diagnostics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Spectral Diagnostics is -8.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spectral Diagnostics is -8.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.03% of the float of Spectral Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Spectral Diagnostics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spectral Diagnostics has recently decreased by 5.87%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spectral Diagnostics does not currently pay a dividend.

Dividend Growth

Spectral Diagnostics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.03% of the float of Spectral Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Spectral Diagnostics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Spectral Diagnostics has recently decreased by 5.87%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Spectral Diagnostics has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Spectral Diagnostics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spectral Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.50% of the stock of Spectral Diagnostics is held by insiders.

EDTXF Stock Analysis - Frequently Asked Questions

How have EDTXF shares performed this year?

Spectral Diagnostics' stock was trading at $0.3474 at the beginning of the year. Since then, EDTXF shares have increased by 69.7% and is now trading at $0.5896.
View the best growth stocks for 2025 here.

How were Spectral Diagnostics' earnings last quarter?

Spectral Diagnostics Inc. (OTCMKTS:EDTXF) announced its earnings results on Friday, May, 9th. The company reported ($0.03) EPS for the quarter. The company earned $0.40 million during the quarter.

How do I buy shares of Spectral Diagnostics?

Shares of EDTXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/09/2025
• Today: 6/24/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:EDTXF
• Previous Symbol: OTCMKTS:DIAGF
• CIK: N/A
• Web: www.spectraldx.com
• Phone: (416) 626-3233
• Fax: 416-626-7383
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.07)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.24 million
• Net Margins: -1,078.10%
• Pretax Margin: -1,077.59%
• Return on Equity: N/A
• Return on Assets: -336.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.09
• Quick Ratio: 0.08

Sales & Book Value

• Annual Sales: $1.67 million
• Price / Sales: 100.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -8.42

Miscellaneous

• Outstanding Shares: 285,520,000
• Free Float: 281,237,000
• Market Cap: $168.34 million
• Optionable: Not Optionable
• Beta: 0.23